About Meridian
Built by operators. For founders.
Meridian Rare Advisors was founded on a simple premise: early-stage biotechs deserve the same caliber of commercialization expertise that large pharma takes for granted.
Founder & Managing Director
Principal Advisor
With over two decades at the intersection of rare disease science and commercial strategy, our founder has guided more than 15 programs from clinical stage through successful market entry. That experience spans global pharmaceutical leaders and first-time biotech founders alike — and it informs every engagement we take on.
Before founding Meridian, our principal held senior commercial and strategy roles at leading biopharma organizations, where he led launch teams, developed go-to-market models, and hired sales, TLL, and genetics professionals to navigate rare and ultra-rare therapies. He has been a trusted advisor to boards, investors, and management teams navigating the most consequential decisions in a drug's lifecycle.
Meridian was built to bring that depth of experience directly to the companies that need it most — lean, early-stage teams who are moving fast and cannot afford to learn commercialization the hard way.
Our Philosophy
Strategy without execution is just theory.
Rare disease is a different discipline.
The playbooks built for primary care and specialty pharma do not translate to rare disease. Patient populations are small, clinical evidence is limited, and payer dynamics are unique. We bring frameworks purpose-built for this environment.
Speed matters. Precision matters more.
Early-stage biotechs move fast — and they should. But speed without strategic clarity creates expensive course corrections. We help you move quickly in the right direction, with the evidence and rationale to bring investors and partners along.
We work alongside you, not above you.
We are not a traditional consulting firm that delivers a report and disappears. We embed with your team, attend your meetings, and stay accountable to outcomes — not just deliverables.
The patient is always the north star.
Every commercial decision we help you make ultimately affects whether a patient gets access to a therapy that could change their life. That responsibility shapes how we think about every engagement.
Ready to work together?
Let's talk about where your program is today and where it needs to go.